India Generic Drugs Market Size, Share and Forecast 2020-2026
India
generic drugs market is estimated to grow at a CAGR of nearly 9.5% during
the forecast period. A significant rise in the incidences of chronic diseases
is driving the demand for generic drugs in the country. The National Cancer
Registry Programme estimates that there will be 13.9 lakh new cancer incidences
reported in India in 2020, which is expected to rise to 15.7 lakh by 2025. This
leads to increasing demand for generic drugs that are playing a crucial role in
cancer treatment. For instance, in everyday practice, patients with early-stage
breast cancer, and children suffering from acute lymphoblastic leukemia are
treated and cured with generics. In cancer care, generic drugs are also
significantly used in supportive care beyond chemotherapy.
To Request a Sample of our
Report on India Generic Drugs Market:
https://www.omrglobal.com/request-sample/india-generic-drugs-market
The increasing prevalence of
diabetes is also supporting to drive market growth. As per the International
Diabetes Federation (IDF), the total cases of diabetes reported in adults in
India was nearly 77 million in 2019. This leads to increasing demand for generic
medicines for diabetes which include Tolazamide (Tolinase), Acetohexamide, and
Glimepiride (Amaryl). Additionally, several generic equivalents of the drug
metformin (earlier sold only as Glucophage XR or Glucophage) are now available.
Scope of the India
Generic Drugs Market
Market Coverage
·
Market number available for 2019-2026
·
Base year- 2019
·
Forecast period- 2020-2026
·
Segment Covered- By Application and Route of
Administration
·
Competitive Landscape- Mylan N.V., Teva
Pharmaceutical Industries Ltd., Lupin Ltd., Aurobindo Pharma Ltd., and Sun
Pharmaceutical Industries Ltd.
Recent Strategic
Initiatives in the India Generic Drugs Market
·
In July 2020, Cipla declared the launch of its
generic version of antiviral drug remdesivir, Cipremi, at $53.3 per 100 mg vial.
This makes it among the lowest cost versions for COVID-19 treatment and Cipla
is looking to deliver more than 80,000 vials within the first month.
·
In July 2020, Mylan launched a generic version
of Remdesivir drug, Desrem, in India for treatment of COVID-19 patients. This
drug will be available at a price of nearly $64.2 per 100 mg vial as against
Hetero’s Covifor at nearly 72.2 per 100 mg vial and Cipla’s Cipremi costing
nearly $53.3 per 100 mg vial.
(Get 15% Discount on Buying
this Report)
A full Report of India
Generic Drugs Market is Available at: https://www.omrglobal.com/industry-reports/india-generic-drugs-market
India Generic
Drugs Market-Segmentation
By Application
·
Cancer
·
CVD
·
Musculoskeletal Diseases
·
Infectious Diseases
·
Neurology
·
Diabetes
·
Others
By Route of
Administration
·
Oral
·
Topical
·
Injectable
·
Inhaler
Company Profiles
·
Aurobindo Pharma Ltd.
·
Biocon Ltd.
·
Cadila Healthcare Ltd. (CHL)
·
Cipla Ltd.
·
Dr. Reddy's Laboratories Ltd.
·
Glenmark Pharmaceuticals Ltd.
·
Lupin Ltd.
·
Mylan N.V.
·
Sun Pharmaceutical Industries Ltd.
·
Teva Pharmaceutical Industries Ltd.
Reasons
to buy from us –
1.
We cover more than 15 major industries, further segmented into more than 90
sectors.
2.
More than 120 countries are for analysis.
3.
Over 100+ paid data sources mined for investigation.
4.
Our expert research analysts answer all your questions before and after
purchasing your report.
For
More Customized Data, Request for Report Customization @ https://www.omrglobal.com/report-customization/india-generic-drugs-market
About Orion
Market Research
Orion Market Research (OMR) is a market research and consulting
company known for its crisp and concise reports. The company is equipped with
an experienced team of analysts and consultants. OMR offers quality syndicated
research reports, customized research reports, consulting and other
research-based services.
Media
Contact:
Company
Name: Orion Market Research
Contact
Person: Mr. Anurag Tiwari
Email: info@omrglobal.com
Contact no: +91 7803040404
Comments
Post a Comment